Skip to Content
MilliporeSigma
All Photos(1)

Documents

Y0001062

Losartan potassium

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2-Butyl-4-chloro-1-{[2′-(1H-tetrazol-5-yl)(1,1′-biphenyl)-4-yl]methyl}-1H-imidazole-5-methanol monopotassium salt, 2-butyl-4-chloro-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]- 1H-Imidazole-5-methanol potassium salt, DuP 753, MK 954, Potassium 5-(4′-((2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-yl)tetrazol-1-ide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H22ClKN6O
CAS Number:
124750-99-8
Molecular Weight:
461.00
Beilstein/REAXYS Number:
5845770
MDL number:
MFCD02092704
UNSPSC Code:
41116107
PubChem Substance ID:
329831243
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

losartan

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)-c3ccccc3-c4nnnn4[K]

InChI

1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1

InChI key

OXCMYAYHXIHQOA-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Losartan potassium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Losartan potassium is an orally available, potent, and selective competitive angiotensin II receptor type 1 (AT1) antagonist. Losartan potassium is used for treatment of hypertension.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001076

Losartan for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001072

Losartan impurity D, European Pharmacopoeia (EP) Reference Standard

1370462

Losartan potassium, United States Pharmacopeia (USP) Reference Standard

1695343

Triphenylmethanol, United States Pharmacopeia (USP) Reference Standard

1370473

Losartan Related Compound A, United States Pharmacopeia (USP) Reference Standard

1370495

Losartan Related Compound C, United States Pharmacopeia (USP) Reference Standard

1370484

Losartan Related Compound B, United States Pharmacopeia (USP) Reference Standard

1370509

Losartan Related Compound D, United States Pharmacopeia (USP) Reference Standard

1370510

Losartan Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP867

Losartan potassium, British Pharmacopoeia (BP) Reference Standard

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

Hydrochlorothiazide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1032

Hydrochlorothiazide

Valsartan ≥98% (HPLC)

Sigma-Aldrich

SML0142

Valsartan

vibrant-m

Y0001719

Rosuvastatin calcium

4-Chloro-7-nitrobenzofurazan 98%

Sigma-Aldrich

163260

4-Chloro-7-nitrobenzofurazan

Satoshi Terada et al.
The Journal of bone and joint surgery. American volume, 95(11), 980-988 (2013-06-20)
Muscle contusions are a common type of muscle injury and are frequently encountered in athletes and military personnel. Although these injuries are capable of healing in most instances, incomplete functional recovery often occurs because of the development of fibrosis in
Christiane Pees et al.
The American journal of cardiology, 112(9), 1477-1483 (2013-07-23)
Since 2008, when angiotensin II type I receptor blockade with losartan was introduced in the prevention of cardiovascular manifestation of Marfan syndrome (MFS), a specific treatment to address the cardiovascular lesions became available. The present study aimed to compare the
K L Goa et al.
Drugs, 51(5), 820-845 (1996-05-01)
Losartan potassium is an orally active, nonpeptide angiotensin II (AII) receptor antagonist. It is the first of a new class of drugs to be introduced for clinical use in hypertension. This novel agent binds competitively and selectively to the AII
M Burnier et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 13(1), S23-S28 (1995-07-01)
The evaluation of a new drug in normotensive volunteers provides important pharmacodynamic and pharmacokinetic information as long as the compound has a specific mechanism of action which can be evaluated in healthy subjects as well as in patients. The purpose
L M Burrell
Drug safety, 16(1), 56-65 (1997-01-01)
Losartan potassium is the first of a new class of orally active antihypertensive drugs which antagonise the action of angiotensin (AT) II at the AT1 receptor subtype. Losartan potassium is converted by the liver to the active metabolite E-3174, which
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service